Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer- term studies

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1101-1109

  Nemunaitis, John ^a   Poole, Christopher ^b   Primrose, John ^c   Rosemurgy, Alexander ^d   Malfetano, John ^e   Brown, Peter ^f   Berrington, Amy ^f   Cornish, Alan ^f   Lynch, Kevin ^f,h   Rasmussen, Henrik ^f   Kerr, David ^b   Cox, David ^g   Millar, Andrew ^f  

^a TEXAS ONCOLOGY   (United States)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c University Surgical Unit   (United Kingdom)

^d TAMPA GENERAL HOSPITAL   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f British Biotechnology   (United Kingdom)

^g NUFFIELD COLLEGE   (United Kingdom)

^h British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; ORAL DRUG ADMINISTRATION; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RASH;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 14444284598     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Brown, P. D., and Giavazzi, R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol., 6: 967-974, 1995.
2. Matrisian, L. M. Metalloproteinases and their inhibitors in matrix remodelling. Trends Genet., 6: 121-125, 1993.
3. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P., and Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug Dev. Today, 1: 16-26, 1996.
4. Powell, W. C., and Matrisian, L. M. Complex roles of matrix metalloproteinases in tumour progression. Curr. Top. Microbiol. Immunol., 213: 1-21, 1996.
5. Chirivi, R. S., Garofalo, A., Crimmin, M. J., Bawden, L. J., Brown, P. D., and Giavazzi, R. G. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int. J. Cancer, 58: 460-464, 1994.
6. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P., and Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst., 87: 293-298, 1995.
7. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M., Brown, P. D., and Hardcastle, J. D. Inhibition of organ invasion by metalloproteinase inhibitor, BB-94 (batimastat) in two human colon metastasis models. Cancer Res., 55: 3629-3633, 1995.
8. Sledge, G. W., Qulali, M., Goulet, R., Bone, E. A., and Fife, R. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Res., 87: 1546-1550, 1995.
9. Eccles, S. A., Box, G. M., Court, W. J., Bone, E. A., Thomas, W., and Brown, P. D. Control of lymphatic and hematogenous metastases of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). Cancer Res., 56: 2815-2822, 1996.
10. Simon, R. Design and conduct of clinical trials. In: V.T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Ed. 4, pp. 418-440. Philadelphia: J. B. Lippincott, 1993.
11. Millar, A. W., Brown, P. D., Moore, J., Galloway, W. A., Cornish, A. G., Lenehan, T. J., and Lynch, K. P. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol., 45: 21-26, 1998.
12. Rubin, S. C., Hoskins, W. J., and Hakes, T. B. CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am. J. Obstet. Gynecol., 160: 667-671, 1989.
13. Goldenberg, D. M., Neville, A., and Carter, A. CEA (carcinoembryonic antigen). Its role as a marker in the management of cancer. J. Cancer Res. Clin. Oncol., 101: 239-242, 1981.
14. Ward, U., Primrose, J. N., Finan, P. J., Perren, T. J., Selby, P., Purves, D. A., and Cooper, E. H. The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br. J. Cancer, 67: 1132-1135, 1993.
15. Stamey, T. A., Kabalin, J. W., and McNeal, J. E. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II radical prostatectomy treated patients. J. Urol., 141: 1076-1083, 1989.
16. Steinberg, W., Gelfand, R., and Anderson, K. Comparison of the sensitivity and specificity of the CA 19-9 and CEA assays in detecting cancer of the pancreas. Gastroenterology, 90: 343-349, 1986.
17. Agresti, A. An introduction to categorical data analysis. In: V. Barnett, R. Bradley, N. Fisher, J. Hunter, J. Kadane, D. Kendall, D. Scott, A. Smith, J. Tengels, and G. Watson (eds.), Wiley Series in Probability and Statistics, pp. 53-70. New York: Wiley, 1996.
18. Gore, M., A'Hern, R., Stankiewicz, M., and Slevin, M. Tumour marker levels during marimastat therapy. Lancet, 348: 263, 1996.
19. Millar, A., Brown, P., Cornish, A., and Baillet, M. Tumour marker levels during marimastat therapy-reply. Lancet, 348: 263-264, 1996.